

3-4 Week Rabbit Complement Lyophilized

Product Data Sheet · P/N 74125 Rev 01 · Reissued 2026-09-19 (layout only)

Product code	Pack size
31064-2	2 mL
31064-5	5 x 2 mL

Description

Complement is produced under controlled conditions from large pools of New Zealand White rabbits that are 21-28 days old. This provides a product that has low heterophile antibody activity for many applications, including use in bactericidal and opsonization assays.

Physical State

Dry powder

Testing

Hemolytic: Titer $\geq$ 1:16

Endotoxin: $\leq$ 1.0 EU/mL

Mycoplasma: Negative

Viral: Negative

Application Notes

Reconstitute with 2 mL filtered, deionized water. This product is manufactured using a combination of sterile filtration and aseptic filling, however is sold as non-sterile. Reconstituted complement may be filtered as needed depending on assay requirements and either used immediately or aliquoted and frozen. Repeated freeze-thaw cycles of reconstituted product are not recommended.

Reconstituted complement is stable for up to 1 hour at 4 °C to 25 °C, as measured by hemolytic titer using sensitized sheep RBCs, though it is recommended to maintain the reconstituted product on ice at all times for best results.

Packaging

2 mL glass vials, 1 or 5 vials per package

Storage Temperature

Ambient temperature for up to 5 weeks; -20 °C or below for long term storage

Shipping Conditions

Refrigerant gel packs

Expiration

The functional activity of lyophilized 3-4 week rabbit complement, as measured by hemolytic titer using sensitized sheep RBCs, is maintained for 5 weeks when the product is stored at ambient temperature. Storage temperature of at least 4 °C or below is recommended to prolong shelf life of the lyophilized powder.

Product quality is guaranteed to meet Pel-Freez Biologicals' specifications for 1 year from the date of receipt by the customer as long as the product is stored in accordance with the indicated storage conditions.

References

Hirve S, Bavdekar A, Pandit A, Juvekar S, Patil M, Preziosi MP, Tang Y, Marchetti E, Martellet L, Findlow H, Elie C, Parulekar V, Plikaytis B, Borrow R, Carlone G, Kulkarni PS, Goel A, Suresh K, Beri S, Kapre S, Jadhav S, Preaud JM, Viviani S, LaForce FM. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children

aged 2-10 years: a phase II/III double-blind randomized controlled trial. *Vaccine*. 2012 Oct 5;30(45):6456-60.

Romero-Steiner, S., C. E. Frasch, G. Carlone, R. A. Fleck, D. Goldblatt, and M. H. Nahm. 2006. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. *Clin. Vaccine Immunol.* 13:165-169.

Romero-Steiner, S., D. LiButti, L.B. Pais, J. Dykes, P. Anderson, J.C. Whitin, H.L. Keyserling, and G.M. Carlone. 1997. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against *Streptococcus pneumoniae* using differentiated HL-60 cells. *Clin. Diagn. Lab. Immunol.* 4:415-422.

Burton R.L., Nahm M.H.. *Clin Vaccine Immunol.* 2012 Jun;19(6):835-41. Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in *Streptococcus pneumoniae* serotype 20.

For research use or further manufacturing only. Not for use in diagnostic procedures, or for human or animal consumption.